RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS-C UNRESPONSIVE TO ALFA INTERFERON

被引:71
作者
CAMPS, J
GARCIA, N
RIEZUBOJ, JI
CIVEIRA, MP
PRIETO, J
机构
[1] CLIN UNIV PAMPLONA,DEPT MED,LIVER UNIT,PAMPLONA,SPAIN
[2] UNIV NAVARRA,SCH MED,PAMPLONA,SPAIN
关键词
HEPATITIS C VIRUS RNA; VIRAL REPLICATION; AMINOTRANSFERASES; CIRRHOSIS;
D O I
10.1016/S0168-8278(05)80550-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
For the 30-50% of patients with chronic hepatitis C who do not respond to a-interferon therapy there is no alternative treatment. Some previously untreated patients have shown a biochemical response to ribavirin, but the antiviral effects of this substance on alpha-interferon-resistant cases is largely unknown. Twelve patients with chronic hepatitis C who had not responded to a 6-12 month course of cr-interferon were included in this study. Oral ribavirin was administered at a dose of 16 mg/kg per day for 6 or 9 months. Aminotransferase levels had not significantly changed during interferon therapy but decreased significantly during ribavirin treatment (mean alanine aminotransferase at baseline, 102 +/- 18 IU/l vs. 55 +/- 14 IU/l at 6 months; P = 0.0001). Aminotransferase levels became normal in 6 cases (50%), significantly decreased in 3 patients (25%), and did not significantly change in the remaining 3 cases (25%). All patients with normalized aminotransferase values relapsed after ribavirin was discontinued and aminotransferase activity returned to pretreatment levels. Before therapy serum hepatitis C virus RNA was detected by polymerase chain reaction in 10 cases. None of them had cleared viral RNA when tested following 3, 6 and 9 months of ribavirin therapy. Side-effects were mild and reversible. In conclusion, about half of the patients with chronic hepatitis C who are unresponsive to cy-interferon show a clear-cut biochemical response after 6-9 months of ribavirin administration. However, ribavirin does not clear circulating hepatitis C virus RNA and relapses occur after withdrawal. Therefore, since ribavirin alone does not appear to suppress viral replication, despite its biochemical effect, further studies should be made in combination with other antiviral substances.
引用
收藏
页码:408 / 412
页数:5
相关论文
共 32 条
  • [11] ESTEBAN JI, 1989, LANCET, V2, P292
  • [12] DETECTION OF HEPATITIS-C VIRAL SEQUENCES IN BLOOD DONATIONS BY NESTED POLYMERASE CHAIN-REACTION AND PREDICTION OF INFECTIVITY
    GARSON, JA
    TEDDER, RS
    BRIGGS, M
    TUKE, P
    GLAZEBROOK, JA
    TRUTE, A
    PARKER, D
    BARBARA, JAJ
    CONTRERAS, M
    ALOYSIUS, S
    [J]. LANCET, 1990, 335 (8703) : 1419 - 1422
  • [13] ENHANCED DETECTION BY PCR OF HEPATITIS-C VIRUS-RNA
    GARSON, JA
    RING, C
    TUKE, P
    TEDDER, RS
    [J]. LANCET, 1990, 336 (8719) : 878 - 879
  • [14] TREATMENT OF CHRONIC TYPE-C HEPATITIS WITH ALPHA INTERFERON
    HOOFNAGLE, JH
    DIBISCEGLIE, AM
    [J]. SEMINARS IN LIVER DISEASE, 1989, 9 (04) : 259 - 263
  • [15] USE OF CONSERVED SEQUENCES FROM HEPATITIS-C VIRUS FOR THE DETECTION OF VIRAL-RNA IN INFECTED SERA BY POLYMERASE CHAIN-REACTION
    INCHAUSPE, G
    ABE, K
    ZEBEDEE, S
    NASOFF, M
    PRINCE, AM
    [J]. HEPATOLOGY, 1991, 14 (04) : 595 - 600
  • [16] AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS
    KUO, G
    CHOO, QL
    ALTER, HJ
    GITNICK, GL
    REDEKER, AG
    PURCELL, RH
    MIYAMURA, T
    DIENSTAG, JL
    ALTER, MJ
    STEVENS, CE
    TEGTMEIER, GE
    BONINO, F
    COLOMBO, M
    LEE, WS
    KUO, C
    BERGER, K
    SHUSTER, JR
    OVERBY, LR
    BRADLEY, DW
    HOUGHTON, M
    [J]. SCIENCE, 1989, 244 (4902) : 362 - 364
  • [17] AVOIDING FALSE POSITIVES WITH PCR
    KWOK, S
    HIGUCHI, R
    [J]. NATURE, 1989, 339 (6221) : 237 - 238
  • [18] LASSA FEVER - EFFECTIVE THERAPY WITH RIBAVIRIN
    MCCORMICK, JB
    KING, IJ
    WEBB, PA
    SCRIBNER, CL
    CRAVEN, RB
    JOHNSON, KM
    ELLIOTT, LH
    BELMONTWILLIAMS, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (01) : 20 - 26
  • [19] MCEVOY GK, 1992, AHFS DRUG INFORMATIO, V8, P383
  • [20] OKAMOTO H, 1990, JPN J EXP MED, V60, P167